Details of the Drug Combinations

General Information of This Drug (ID: DMNE56X)

• Drug Name: ABT-263 (DMNE56X)
• Synonyms: Navitoclax; ABT 263; S1001_Selleck; ABT263, Navitoclax; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-({(1R)-3-morpholin-4-yl-1-[(phenylsulfanyl)methyl]propyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide

Indication

Myelofibrosis; ICD 11: 2A20.2; Status: Phase 3 [1]; Relapsed or refractory chronic lymphocytic leukaemia; ICD 11: 2A82.0; Status: Phase 2 [2]; Solid tumour/cancer; ICD 11: 2A00-2F9Z; Status: Discontinued in Phase 2 [3]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

97 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
(-)-englerin A + ABT-263	DCCUPMS	(-)-englerin A	Ewing sarcoma (Cell Line: TC-71)	[4]
ABT-263 + GSK461364	DC4FLDV	GSK461364	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + Gefitinib	DC5MWB3	Gefitinib	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[5]
ABT-263 + Buparlisib	DCAZWM4	Buparlisib	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + GDC0941	DCR8Q33	GDC0941	Glioblastoma (Cell Line: JHH-136)	[5]
ABT-263 + Ruxolitinib	DCMAEI8	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[5]
ABT-263 + Ruxolitinib	DC0CECS	Ruxolitinib	Hodgkin lymphoma (Cell Line: HDLM-2)	[5]
ABT-263 + Ruxolitinib	DCRNL13	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-428)	[5]
ABT-263 + Ombrabulin	DC8EUJD	Ombrabulin	Hodgkin lymphoma (Cell Line: L-1236)	[5]
ABT-263 + Trametinib	DCE4EGP	Trametinib	Glioblastoma (Cell Line: JHH-136)	[5]
ABT-263 + Cladribine	DCLP3U5	Cladribine	Glioblastoma (Cell Line: JHH-136)	[5]
ABT-263 + MK-1775	DCN0QN8	MK-1775	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + JQ1	DCSNW9A	JQ1	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + Carfilzomib	DCXEWGI	Carfilzomib	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + Carfilzomib	DC2UMYK	Carfilzomib	Glioblastoma (Cell Line: JHH-136)	[5]
ABT-263 + Artemether	DC1FBFL	Artemether	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + Panobinostat	DC3OO65	Panobinostat	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + Panobinostat	DCEYZTN	Panobinostat	Hodgkin lymphoma (Cell Line: L-1236)	[5]
ABT-263 + Ym155	DC2GBKX	Ym155	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + Ixazomib	DC48DXX	Ixazomib	Glioblastoma (Cell Line: JHH-136)	[5]
ABT-263 + SCH-900776	DCXBQHP	SCH-900776	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + Eltanexor oral	DC2564G	Eltanexor oral	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + AZD8055	DCBP1UZ	AZD8055	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + AZD8055	DC9LXD0	AZD8055	Glioblastoma (Cell Line: JHH-136)	[5]
ABT-263 + Formononetin	DCBMCCC	Formononetin	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + Everolimus	DCV6NCG	Everolimus	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + CA4P	DC5V4CT	CA4P	Glioblastoma (Cell Line: JHH-136)	[5]
ABT-263 + BN-2629	DCNTBX3	BN-2629	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + GDC-0084	DCG0S39	GDC-0084	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + Topetecan	DCLBVAK	Topetecan	Glioblastoma (Cell Line: JHH-136)	[5]
ABT-263 + Pralatrexate	DCOCU9T	Pralatrexate	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + Steroid derivative 1	DCYLZPV	Steroid derivative 1	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + Cantharidin	DC6DJ3E	Cantharidin	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + Exherin	DCV1HGS	Exherin	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + TAK-733	DCYLPJQ	TAK-733	Glioblastoma (Cell Line: JHH-136)	[5]
ABT-263 + AT7519	DCKKO2B	AT7519	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + SCH 727965	DCAZ03L	SCH 727965	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + SCH 727965	DCTE8D0	SCH 727965	Hodgkin lymphoma (Cell Line: L-1236)	[5]
ABT-263 + Daporinad	DCMP029	Daporinad	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + LY2523355	DCMUE0K	LY2523355	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + Docetaxel	DCYVER0	Docetaxel	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + THAPSIGARGIN	DC78NLX	THAPSIGARGIN	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + Etoposide	DCFUXQB	Etoposide	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + AEE-788	DC1WK8E	AEE-788	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + GDC-0980/RG7422	DCXBUDT	GDC-0980/RG7422	Glioblastoma (Cell Line: JHH-136)	[5]
ABT-263 + PHA-739358	DC6PNZB	PHA-739358	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + Mitomycin	DC7FVA0	Mitomycin	Diffuse large B cell lymphoma (Cell Line: TMD8)	[5]
ABT-263 + Mitomycin	DCIN0QA	Mitomycin	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + OSI-906	DC4KDZK	OSI-906	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + Vincristine	DCVTIAL	Vincristine	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + Pelitinib	DCEC5B4	Pelitinib	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + Pelitinib	DC7G0RK	Pelitinib	Glioblastoma (Cell Line: JHH-136)	[5]
ABT-263 + Verteporfin	DCLT2QL	Verteporfin	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + OSI-027	DC01OF7	OSI-027	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + OSI-027	DCY2Z31	OSI-027	Glioblastoma (Cell Line: JHH-136)	[5]
ABT-263 + AS602868	DCB7DQM	AS602868	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[5]
ABT-263 + AS602868	DCRTZ3D	AS602868	Glioblastoma (Cell Line: JHH-136)	[5]
ABT-263 + GSK2126458	DCK1U54	GSK2126458	Glioblastoma (Cell Line: JHH-136)	[5]
ABT-263 + Nintedanib	DCRTDYP	Nintedanib	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + Ciclopirox	DCF1VBF	Ciclopirox	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[5]
ABT-263 + Tivantinib	DCYS7C3	Tivantinib	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + Bardoxolone methyl	DCYGO5P	Bardoxolone methyl	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + Ispinesib	DC6EMN2	Ispinesib	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + Obatoclax	DC5JNSQ	Obatoclax	Glioblastoma (Cell Line: JHH-136)	[5]
ABT-263 + TG100801	DCYLI3F	TG100801	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + (-)-englerin A	DC7J2O7	(-)-englerin A	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + Decitabine	DCBDE7J	Decitabine	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + Podofilox	DC8N4LC	Podofilox	Glioblastoma (Cell Line: JHH-136)	[5]
ABT-263 + Romidepsin	DCSDWLL	Romidepsin	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + CHS-828	DCVE351	CHS-828	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + NVP-AUY922	DCSGUYD	NVP-AUY922	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + Mitotane	DCJFJI1	Mitotane	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + Doxorubicin	DC7FKC1	Doxorubicin	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + Auranofin	DCA6KJW	Auranofin	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[5]
ABT-263 + LY2874455	DCIDPT7	LY2874455	Ewing sarcoma (Cell Line: TC-71)	[5]
ABT-263 + Cytarabine	DCTNGRL	Cytarabine	Ewing sarcoma (Cell Line: TC-71)	[5]
Bardoxolone methyl + ABT-263	DC7EMQS	Bardoxolone methyl	Hodgkin lymphoma (Cell Line: L-1236)	[4]
Birinapant + ABT-263	DC9DWNN	Birinapant	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
BIX-01294 + ABT-263	DCWJ0FM	BIX-01294	Ewing sarcoma (Cell Line: TC-71)	[4]
Bleomycin + ABT-263	DCW5ILP	Bleomycin	Hodgkin lymphoma (Cell Line: L-1236)	[5]
Dasatinib + ABT-263	DC39A52	Dasatinib	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
Efaproxyn + ABT-263	DCICHEL	Efaproxyn	Ewing sarcoma (Cell Line: TC-71)	[4]
Everolimus + ABT-263	DCL2MHQ	Everolimus	Ewing sarcoma (Cell Line: TC-71)	[4]
Exherin + ABT-263	DCK0FAS	Exherin	Ewing sarcoma (Cell Line: TC-71)	[4]
GDC-0084 + ABT-263	DCL0NWT	GDC-0084	Hodgkin lymphoma (Cell Line: L-1236)	[5]
GDC-0980/RG7422 + ABT-263	DCU9FZP	GDC-0980/RG7422	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
LY2523355 + ABT-263	DCRLRHD	LY2523355	Ewing sarcoma (Cell Line: TC-71)	[4]
MK-2206 + ABT-263	DCKMHR7	MK-2206	Ewing sarcoma (Cell Line: TC-71)	[4]
NVP-AUY922 + ABT-263	DCU6LHC	NVP-AUY922	Ewing sarcoma (Cell Line: TC-71)	[4]
PAC1 + ABT-263	DCQ73C9	PAC1	Glioblastoma (Cell Line: JHH-136)	[4]
Panobinostat + ABT-263	DCCW4U9	Panobinostat	Ewing sarcoma (Cell Line: TC-71)	[4]
Pelitinib + ABT-263	DCB57AA	Pelitinib	Ewing sarcoma (Cell Line: TC-71)	[4]
Pelitinib + ABT-263	DC5H5GM	Pelitinib	Hodgkin lymphoma (Cell Line: L-1236)	[5]
PHA-739358 + ABT-263	DC031MX	PHA-739358	Ewing sarcoma (Cell Line: TC-71)	[4]
RAF265 + ABT-263	DC6RZUK	RAF265	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
RTB101 + ABT-263	DCPY2E2	RTB101	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]
SCH 727965 + ABT-263	DC23P0A	SCH 727965	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[4]

12 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
ABT-263 + Irinotecan	DCSTBKH	Irinotecan	Solid Tumors	[6]
ABT-263 + Ketoconazole	DCUV43Q	Ketoconazole	Lymphoma	[7]
Celecoxib + ABT-263	DCQAUW7	Celecoxib	Myeloproliferative Neoplasm	[8]
Erlotinib + ABT-263	DCZVW5N	Erlotinib	Solid Tumors	[6]
Olaparib + ABT-263	DCYQBQF	Olaparib	High Grade Serous Carcinoma	[9]
Paclitaxel + ABT-263	DC9W36D	Paclitaxel	Solid Tumors	[10]
Ruxolitinib + ABT-263	DCB2W4Q	Ruxolitinib	Myeloproliferative Neoplasm	[8]
Venetoclax + ABT-263	DCCG0Q9	Venetoclax	Myeloid Malignancy	[11]
Venetoclax + ABT-263	DCJPVLH	Venetoclax	Acute Lymphoblastic Leukemia	[12]
ABIRATERONE + ABT-263	DC7NFUT	ABIRATERONE	Prostate Cancer	[13]
ABIRATERONE + ABT-263	DC2J02L	ABIRATERONE	Prostate Cancer	[13]
Ruxolitinib + ABT-263	DCQ6EM6	Ruxolitinib	Myelofibrosis (MF)	[14]

References

• [1] ClinicalTrials.gov (NCT04472598) Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis (TRANSFORM-1). U.S. National Institutes of Health.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8319).
• [3] Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.Nat Rev Drug Discov. 2016 Aug;15(8):533-50.
• [4] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [5] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [6] ClinicalTrials.gov (NCT01009073) A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects
• [7] ClinicalTrials.gov (NCT01021358) A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).
• [8] ClinicalTrials.gov (NCT04041050) A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
• [9] ClinicalTrials.gov (NCT05358639) Combination of Olaparib and Navitoclax in Women With HGSC and TNBC
• [10] ClinicalTrials.gov (NCT00891605) Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors
• [11] ClinicalTrials.gov (NCT05455294) Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
• [12] ClinicalTrials.gov (NCT05054465) A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL
• [13] ClinicalTrials.gov (NCT01828476) Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer
• [14] ClinicalTrials.gov (NCT03222609) A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis